In the highly competitive field of immuno-oncology, one new target in particular has been capturing the attention of industry, investors and clinicians alike as a potential combination partner for PD-1/L1 checkpoint inhibitors: IDO.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?